ECT

Silver Hill Hospital Launches Outpatient Ketamine Treatment Program for Depression

Retrieved on: 
Wednesday, February 14, 2024
Other Health, Research, Men, Managed Care, General Health, Consumer, Mental Health, Hospitals, Science, Women, Seniors, Health, Silver, Hospital, Silver Hill Hospital, Medical director, Ketamine, Electroconvulsive therapy, Patient, Nursing, DSM-IV codes, ECT, Mental, Environment, Depression

Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, has opened its Ketamine Treatment Program , bringing a powerful therapeutic intervention to patients with treatment-resistant depression.

Key Points: 
  • Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, has opened its Ketamine Treatment Program , bringing a powerful therapeutic intervention to patients with treatment-resistant depression.
  • With this opening, Silver Hill joins a select number of hospitals with comprehensive mental health services administering ketamine treatment.
  • In keeping with the environment of restorative care at Silver Hill, the Ketamine Treatment Program was deliberately designed to maximize comfort conducive to healing.
  • “With our research-backed protocol, expert medical staff, and the oversight of Dr. Prueitt, the Ketamine Treatment Program is poised to help patients who have not responded to more traditional depression treatment methods and may have been losing hope.”
    The Silver Hill Hospital Ketamine Treatment Program is available to outpatients, as well as inpatients and residential patients, and it is now accepting referrals.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon

Retrieved on: 
Monday, February 5, 2024
HOPE, Therapy, Patient, New Drug Application, FDA, Ketamine, Dark Enlightenment, NDA, ECT, Suicide, Electroconvulsive therapy, Insurance, DSM-IV codes, Pharmaceutical industry

This is designed with counsel to not be a taxable event for shareholders.

Key Points: 
  • This is designed with counsel to not be a taxable event for shareholders.
  • "Incorporating HOPE Therapeutics is another important step in building value for NRx shareholders.
  • HOPE is dedicated to providing an FDA-approved presentation of IV Ketamine, manufactured to current federal standards, in a diversion- and abuse-deterrent presentation.
  • NRx also expects to convene a shareholder meeting in the coming weeks to vote on the planned structure of the spin-out of Hope Therapeutics and the stock dividend.

Kontron Powers Truminds’ Software for Energy-Efficient Private 5G Wireless Networks by Leveraging Napatech SmartNICs

Retrieved on: 
Tuesday, January 23, 2024
Data Management, Technology, IOT (Internet of Things), Online Privacy, Telecommunications, Software, Networks, Internet, Mobile, Wireless, 5G, Hardware, UPF, SMF, OEM, UDM, Networking hardware, Mining, MWC, Business development, ECT, Original equipment manufacturer, Airport, CPU, AMF, Engineering

Enterprises in manufacturing/industrial, broadcasting, retail, mining, and healthcare are adopting private 5G wireless networks for reliability and guaranteed coverage.

Key Points: 
  • Enterprises in manufacturing/industrial, broadcasting, retail, mining, and healthcare are adopting private 5G wireless networks for reliability and guaranteed coverage.
  • Truminds, a renowned name in specialized engineering solutions, enhances both cost-performance and energy efficiency using Kontron servers designed for edge deployments.
  • Kontron’s ME1310 multi-access edge server, powered by Intel® Xeon® D-2700 processors, addresses the challenges of private networks with its rugged, power-efficient design.
  • The deployment includes Smart Network Interface Cards (SmartNICs) from Napatech which offload and accelerate the compute-intensive User Plane Function (UPF) using Truminds’ TruCore.

NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco

Retrieved on: 
Tuesday, January 2, 2024
ECT, Partnership, Drug development, Plasma protein binding, FDA, European, Therapy, REMS, Keynote, Dark Enlightenment, MPH, Mitigation, Pharmaceutical industry

"Ketamine's efficacy was so dramatic that ketamine became a standard of care ahead of the large clinical trials required for drug approval.

Key Points: 
  • "Ketamine's efficacy was so dramatic that ketamine became a standard of care ahead of the large clinical trials required for drug approval.
  • Ketamine, as expected, now been demonstrated to be dramatically superior to placebo in large clinical trials.
  • What could not be predicted is that ketamine has been shown to be at least as good as (i.e.
  • We have partnered with Nephron Pharmaceuticals to develop a modern, single use, diversion- and tamper-resistant formulation of ketamine.

NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression

Retrieved on: 
Tuesday, December 19, 2023
Psychiatry, ECT, BMJ, Partnership, American Journal, Depression, FDA, Ketamine, NDA, Hospital, Literature, Medical journal, Columbia University, Suicidal ideation, The BMJ, Dark Enlightenment, SSI, Patient, Suicide, Pharmaceutical industry

This represents NRx's second well-controlled trial demonstrating the efficacy of IV Ketamine in this indication.

Key Points: 
  • This represents NRx's second well-controlled trial demonstrating the efficacy of IV Ketamine in this indication.
  • These data mirror the results recently reported by a French consortium of hospitals who tested ketamine vs. placebo in acutely suicidal patients.
  • NRx established a similar data licensing agreement in September, 2023 ( NRx Ketamine Data Sharing, France ).
  • This filing will include manufacturing and stability data from the Company's partnership with Nephron Pharmaceuticals (West Columbia, SC).

Kontron Announces the Development of a COM-HPC Mini Module

Retrieved on: 
Wednesday, November 15, 2023
Technology, Engineering, Manufacturing, Audio, Video, Other Health, Hardware, Health, Electronic Design Automation, Data Management, Thunderbolt, PCI Express, Mini, Gigabit Ethernet, Industrial internet of things, PICMG, DisplayPort, ECT, City, Software, Kontron

Kontron , a leading global provider of IoT/Embedded Computer Technology (ECT), announces the development of a COM-HPC Mini module based on the COM-HPC 1.2 specification approved by PICMG on 6 October 2023.

Key Points: 
  • Kontron , a leading global provider of IoT/Embedded Computer Technology (ECT), announces the development of a COM-HPC Mini module based on the COM-HPC 1.2 specification approved by PICMG on 6 October 2023.
  • With the ratification of the COM-HPC 1.2 specification to COM-HPC Mini, PICMG has significantly extended the high-performance standard.
  • The COM-HPC Mini module measures only 95 mm x 70 mm and thus complements the COM-HPC standard with a more compact format compared to the COM-HPC client and server formats.
  • "COM-HPC Mini enables the integration of ultra-high-performance COMs in the smallest application areas.

Park Royal Hospital Offers Inpatient & Outpatient Electroconvulsive Therapy

Retrieved on: 
Tuesday, November 7, 2023
The American Journal of Psychiatry, Patient, Suicide, Education, The Lancet, Psychiatry, Electricity, Fear, Electroconvulsive therapy, Risk, Suicidal ideation, ECT, Brain, Depression, Safety, American Journal, Anesthesia, Death, Mental health, Pharmaceutical industry

FORT MYERS, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Park Royal Hospital, a premier provider of mental health and addiction treatment, is pleased to offer electroconvulsive therapy (ECT) for patients.

Key Points: 
  • FORT MYERS, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Park Royal Hospital, a premier provider of mental health and addiction treatment, is pleased to offer electroconvulsive therapy (ECT) for patients.
  • At Park Royal Hospital, ECT is available on an inpatient and outpatient basis and is delivered by a trained team of professionals.
  • Electroconvulsive therapy involves using a mild electrical current to stimulate the brain to produce a brief seizure while the patient is under general anesthesia.
  • Those who are interested in receiving ECT at Park Royal Hospital do not need a referral to inquire about treatment and can begin the admissions process anytime.

TrustPoint Hospital Offers Electroconvulsive Therapy in Inpatient & Outpatient Programs

Retrieved on: 
Tuesday, November 7, 2023
The American Journal of Psychiatry, Suicide, The Lancet, Psychiatry, Electroconvulsive therapy, Quality of life, Risk, Suicidal ideation, ECT, Depression, Safety, American Journal, Patient, Mental health, Pharmaceutical industry, Nursing

MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are struggling with severe symptoms of certain mental health disorders.

Key Points: 
  • MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are struggling with severe symptoms of certain mental health disorders.
  • TrustPoint Hospital offers inpatient and outpatient programs for patients who have a range of behavioral health concerns and need focused support.
  • ECT is available in all TrustPoint programs for adults age 18 and older.
  • “At TrustPoint Hospital, we’re committed to providing safe, efficient care that can positively transform patients’ quality of life,” said Brianna Motley, director of business development at TrustPoint.

EDC report: Global public policies are powering the cleantech race and incentivizing record investment

Retrieved on: 
Thursday, October 19, 2023
EDC, Public policy, Organization, R, Economics, Environment, Growth, Private sector, CEW, ECT, Investment, Renewable energy

As outlined in Canadian cleantech: Powering progress , 2022 saw record investment in Canada’s cleantech sector at $1.2 billion—the highest recorded since 2018.

Key Points: 
  • As outlined in Canadian cleantech: Powering progress , 2022 saw record investment in Canada’s cleantech sector at $1.2 billion—the highest recorded since 2018.
  • From Oct. 30 to Nov. 6, EDC will host the 2023 Cleantech Export Week (CEW) themed Powering collaboration and accelerating progress .
  • *Note: The cleantech report is an annual review of the global and Canadian cleantech industry produced by EDC’s Economics team.
  • The report analyzes data from leading organizations, providing expert commentary on the current status of and future potential for the Canadian cleantech sector.

Pioneer Energy’s Emission Control Treater Featured in the Journal of Petroleum Technology

Retrieved on: 
Tuesday, October 10, 2023
Green Technology, Oil, Gas, Environmental Health, Energy, Environment, Pressure, ECT, Denver, Carbon, Society of Petroleum Engineers, Society, EPA, Ozone, Control, Journal, Pioneer Energy, Pioneer, Water, Renewable energy

This new technology, the Emission Control Treater™ (ECT), has been detailed in a case study published in the October 2023 issue of the Journal of Petroleum Technology.

Key Points: 
  • This new technology, the Emission Control Treater™ (ECT), has been detailed in a case study published in the October 2023 issue of the Journal of Petroleum Technology.
  • The ECT promises to transform the landscape of oil and gas production, significantly reducing emissions while also increasing operational efficiency.
  • Pioneer Energy’s Emission Control Treater™ (ECT) offers the answer to this challenge.
  • “We are very happy that the Society of Petroleum Engineers has selected our case study of the pilot deployment of the Emission Control Treater to be featured in the Journal of Petroleum Technology.